Instructions for use Task and The Ast Track

3-CAT ELISA Rest Track

Presse use of the part of the par



BA E-6600R







Table of contents

1.	Introduction	3
1.1	Intended use and principle of the test	3
1.2	Background	3
2.	Procedural cautions, guidelines, warnings and limitations	3
2.1	Procedural cautions, guidelines and warnings	3
2.2	Limitations	4
2.2.1	Interfering substances and proper handling of specimens	4
2.2.2	Drug and food interferences	4
2.2.3	High-Dose-Hook effect	4
3.	Storage and stability	4
4.	Materials	4
4.1	Contents of the kit	4
4.2	Calibration and Controls	6
4.3	Additional materials required but not provided in the kit	6
4.4	Additional equipment required but not provided in the kit	6
5.	Sample collection, handling and storage	7
6.	Test procedure	7
6.1	Preparation of reagents and further notes	7
6.2	Sample preparation, extraction and acylation	8
6.3	Adrenaline ELISA	8
6.4	Noradrenaline ELISA	9
6.5	Dopamine ELISA	9
7.	Calculation of results	9
7.1	Typical standard curve	10
8.	Control samples	10
9.	Assay characteristics	10
9.1	Performance data	10
10.	References/Literature	12
11.	Changes	13
	7,0	
	"HE	
	At the second of	
	150	
9	Interfering substances and proper handling of specimens Drug and food interferences High-Dose-Hook effect Storage and stability Materials Contents of the kit Calibration and Controls Additional materials required but not provided in the kit Additional equipment required but not provided in the kit Sample collection, handling and storage Test procedure Preparation of reagents and further notes Sample preparation, extraction and acylation Adrenaline ELISA Noradrenaline ELISA Calculation of results Typical standard curve Control samples Assay characteristics Performance data References/Literature Changes Aleaber The Additional provided in the kit Additional materials required but not provided in the kit Additional materials required but not provided in the kit Additional equipment required but not provided in the kit Additional materials required but not provided in the kit	

Version: 20.0-r *Effective: 2025-05-20* **2 / 13**

Related Products:

- Adrenaline ELISA Fast Track
- Noradrenaline ELISA Fast Track
- Dopamine ELISA Fast Track
- 2-CAT ELISA Fast Track

Introduction

Intended use and principle of the test 1.1

Enzyme Immunoassay for the quantitative determination of adrenaline (epinephrine), noradrenaline (norepinephrine) and dopamine in plasma and urine.

Adrenaline (epinephrine), noradrenaline (norepinephrine) and dopamine are extracted by using a cis-diol-specific affinity gel, acylated and then converted enzymatically.

The subsequent competitive ELISA uses the microtiter plate format. The antigen is bound to the solid phase of the microtiter plate. The acylated standards, controls and samples compete with the solid phase bound analytes for a fixed number of antibody binding sites. After the system is in equilibrium, free antigen and free antigentantibody complexes are removed by washing. The antibody bound to the solid phase is detected by an antipabbit IgGperoxidase conjugate using TMB as a substrate resulting in a colour reaction. The reaction is monitored at a wavelength of 450 nm.

Quantification of unknown samples is achieved by comparing their absorbance with a reference curve prepared with known standard concentrations. Manual processing of the ELISA is recommended. The use of automatic laboratory equipment is the responsibility of the user.

This product is not intended to clinical diagnoses.

Background

In humans the catecholamines adrenaline (epinephrine), noradrenaline (norepinephrine) and dopamine are neurotransmitters of the sympathetic nervous system and are involved in many physiological processes. The sympathetic nervous system sets the body to a heightened state of alert, also called as the body's fight-or-flight response.

In the human body the catecholamines and their metabolites indicate the adaptation of the body to acute and chronic stress.

Procedural cautions, guidelines, warnings and limitations <u>2.</u>

Procedural cautions, guidelines and warnings 2.1

- This kit is intended for professional use only. Users should have a thorough understanding of this protocol for (1)the successful use of this kit. Only the test instruction provided with the kit is valid and must be used to run the assay. Reliable performance will only be attained by strict and careful adherence to the instructions provided.
- The principles of Good Laboratory Practice (GLP) must be followed. (2)
- In order to reduce exposure to potentially harmful substances, wear lab coats, disposable protective gloves (3) and protective glasses where necessary.

 All kit reagents and specimens should be brought to room temperature and mixed gently but thoroughly
- (4)before use. For dilution or reconstitution purposes, use deionized, distilled, or ultra-pure water. Avoid repeated freezing and thawing of reagents and specimens.
- The microplate contains snap off strips. Unused wells must be stored at 2 8 °C in the sealed foil pouch with (5) desiccant and used in the frame provided. Microtiter strips which are removed from the frame for usage should be marked accordingly to avoid any mix-up.
- Standards, Controls and specimen samples should be assayed in duplicate. (6)
- Once the test has been started, all steps should be completed without interruption. Make sure that the required (7) reagents, materials, and devices are prepared for use at the appropriate time.
- Incubation times do influence the results. All wells should be handled in the same order and time intervals. (8)
- To avoid cross-contamination of reagents, use new disposable pipette tips for dispensing each reagent, (9) sample, standard and control.
- A standard curve must be established for each run.
- The controls should be included in each run and fall within established confidence limits. The confidence limits (11)are listed in the QC-Report provided with the kit.
- Do not mix kit components with different lot numbers within a test and do not use reagents beyond expiry (12)date as shown on the kit labels.
- (13) For information about hazardous substances included in the kit please refer to Safety Data Sheet (SDS). The Safety Data Sheet for this product is made available directly on the website of the manufacturer or upon
- (14) Kit reagents must be regarded as hazardous waste and disposed of according to national regulations.
- (15) In case of any severe damage to the test kit or components, the manufacturer has to be informed in writing, at the latest, one week after receiving the kit. Severely damaged single components must not be used for a test run. They must be stored properly until the manufacturer decides what to do with them. If it is decided that they are no longer suitable for measurements, they must be disposed of in accordance with national regulations.

Version: 20.0-r Effective: 2025-05-20 3 / 13

2.2 Limitations

Any inappropriate handling of samples or modification of this test might influence the results.

2.2.1 Interfering substances and proper handling of specimens

Diacma

Samples containing precipitates or fibrin strands or which are hemolytic or lipemic might cause inaccurate results. Hemolytic samples (up to 4 mg/ml hemoglobin), icteric samples (up to 50 mg/dl bilirubin) and lipemic samples (up to 800 mg/dl triglycerides) have no influence on the assay results.

If the concentrations cannot be estimated and there are doubts as to whether the above limit values for hemolytic, icteric or lipemic samples are complied with, the samples should not be used in the assay.

24-hour urine

Please note the sample collection! If the percentage of the final concentration of acid is too high, this will lead to incorrect results for the urine samples.

2.2.2 Drug and food interferences

Medications such as antihypertensive drugs, antidepressants, sympathomimetics, antipsychotics and L-DOPA can affect the concentrations of catecholamines. Discontinuation of medication before the collection period must be discussed with the attending physician.

Caffeinated beverages, alcohol, nicotine, mood-enhancing drugs and catecholamine-rich foods (such as bananas, cheese, nuts, chocolate, tomatoes or beans) can also affect the concentrations of catecholamines and should be avoided from 3 days before and during the collection period (urine). Care should also be taken to avoid stress and physical strain shortly before and during the collection period.

2.2.3 High-Dose-Hook effect

No hook effect was observed in this test.

3. Storage and stability

Store kit and reagents at 2-8 °C until expiration date. Do not use kit and components beyond the expiry date indicated on the kit labels. Once opened, the reagents are stable for 2 months when stored at 2-8 °C. Once the resealable pouch of the ELISA plate has been opened, care should be taken to close it tightly again including the desiccant.

4. Materials

4.1 Contents of the kit

BA D-0090	FOILS	Adhesive Foil ready to use
Content:	Adhesive foils in a res	sealable pouch
Number:	3 x 4 foils	. He
BA E-0030	WASH-CONC 50x	Wash Buffer Concentrate - concentrated 50x

Content: Buffer with a non-ionic detergent and physiological pH

Volume: 3 x 20 ml/vial, purple cap

Content: CONJUGATE Enzyme Conjugate – ready to use

Goat anti-rabbit immunoglobulins conjugated with peroxidase

Volume: 3 x 12 ml/vial red cap

Description: Species is goat

Hazard pictograms:

Signal word: Warning

Hazardous 2-methyl-2H-isothiazol-3-one

ingredients

statements

Hazard H317 May cause an allergic skin reaction.

Precautionary P280 Wear protective gloves.

statements: P302+P352 IF ON SKIN: Wash with plenty of water.

P333+P313 If skin irritation or rash occurs: Get medical advice/attention. P501 Dispose of contents/container to an authorised waste collection point.

Version: 20.0-r Effective: 2025-05-20 4 / 13

SUBSTRATE BA E-0055 Substrate - ready to use Chromogenic substrate containing 3,3',5,5'-tetramethylbenzidine, substrate buffer and Content: hydrogen peroxide Volume: 3 x 12 ml/vial, black cap **BA E-0080** STOP-SOLN Stop Solution - ready to use Content: 0.25 M sulfuric acid Volume: 3 x 12 ml/vial, grey cap **BA E-0131** Ш ADR MN Adrenaline Microtiter Strips - ready to use Content: 1 x 96 wells (12x8) antigen precoated microwell plate in a resealable blue pouch with desiccant **BA E-0231 Ш NAD NMN** Noradrenaline Microtiter Strips - ready to use 1 x 96 wells (12x8) antigen precoated microwell plate in a resealable yellow pouch with Content: desiccant **BA E-0331** Ш DOP Dopamine Microtiter Strips - ready to use 1 x 96 wells (12x8) antigen precoated microwell plate in a resealable green pouch with Content: desiccant **BA E-6110** ADR-AS Adrenaline Antiserum - ready to use Rabbit anti-adrenaline antibody in buffer with proteins and non-mercury preservative, blue Content: coloured Volume: 1 x 6 ml/vial, blue cap Species of antibody is rabbit, species of protein in buffer is bovine Description: **BA E-6210** NAD-AS Noradrenaline Antiserum ready to use Content: Rabbit anti-noradrenaline antibody in buffer with proteins and non-mercury preservative, yellow coloured Volume: 1 x 6 ml/vial, yellow cap Species of antibody is rabbit, species of protein in buffer is bovine Description: **BA E-6310** DOP-AS Dopamine Antiserum - ready to use Content: Rabbit anti-dopamine antibody in buffer with proteins and non-mercury preservative, green coloured Volume: 1 x 6 ml/vial, green cap Species of antibody is rabbit, species of protein in buffer is bovine Description: **BA E-6612** ACYL-REAG Acylation Reagent – ready to use Acylation reagent in PMSO Content: Volume: 1 x 3 ml/vial, white cap **BA R-0050** ADJUST-BUFF Adjustment Buffer - ready to use Content: TRIS buffer Volume: 2 x 4 ml/vial, green cap **BA R-6611** ACYL-BUFF Acylation Buffer - ready to use Buffer with light alkaline pH for the acylation Content: 1 x 20 ml/vial, white cap Volume: BA R-6613 **ASSAY-BUFF** Assay Buffer - ready to use 1 M hydrochloric acid and a non-mercury preservative Volume: 1 x 6 ml/vial, grey cap Hazard

statements:

H314 Causes severe skin burns and eye damage.

GHS05

Danger

pictograms:

Signal word:

Hazard

Version: 20.0-r *Effective: 2025-05-20* **5 / 13**

P280 Wear protective gloves, protective clothing, eye protection. Precautionary

statements: P303+P361+P353 IF ON SKIN (or hair): Take off immediately all contaminated clothing.

Rinse skin with water.

P305+P351+P338 IF IN EYES: Rinse cautiously with water for several minutes. Remove

contact lenses, if present and easy to do. Continue rinsing.

P310 Immediately call a doctor, a POISON CENTER.

P501 Dispose of contents/container to an authorised waste collection point.

COENZYME **BA R-6614** Coenzyme - ready to use

Content: S-adenosyl-L-methionine Volume: 1 x 4 ml/vial, purple cap

BA R-6615 ENZYME Enzyme - lyophilized

Content:

Volume:

Description:

BA R-6617

Content: Volume:

BA R-6618

Content:

Buffer – ready to use

... Jonate
..., vial, brown cap

EXTRACT-PLATE 48 Extraction Plate – ready to use

2 x 48 well plates coated with boronate affinity gel in a resealable pouch

HCL Hydrochloric Acid – ready to use

0.025 M Hydrochloric Acid, yellow coloured

1 x 20 ml/vial, green cap

Ind Controls

In controls **BA R-6619**

Content:

Volume:

Calibration and Controls

Standards and Controls - ready to use

Cat. no.	Component	Colour /Cap	/Cap				Volume/ Vial		
			ADR	NAD	DOP	ADR	NAD	DOP	
BA E-6601	STANDARD A	white	Ø,	0	0	0	0	0	4 ml
BA E-6602	STANDARD B	yellow	N 1	5	10	5.5	30	65	4 ml
BA E-6603	STANDARD C	orange	4	20	40	22	118	261	4 ml
BA E-6604	STANDARD D	blue	15	75	150	82	443	980	4 ml
BA E-6605	STANDARD E	grey	50	250	500	273	1,478	3,265	4 ml
BA E-6606	STANDARD F	black	200	1,000	2,000	1,092	5,910	13,060	4 ml
BA E-6609	STANDARD A/B	purple	-	_	4.5	-	-	29	4 ml
BA E-6651	CONTROL	green	Refer to	QC-Repor	t for exp	ected valu	e and ac	ceptable	4 ml
BA E-6652	CONTROL 2	red	range.						4 ml

adrenaline $[ng/ml] \times 5.46 = adrenaline [nmol/l]$ Conversion:

 $roradrenaline [ng/ml] \times 5.91 = noradrenaline [nmol/l]$

dopamine $[ng/ml] \times 6.53 = dopamine [nmol/l]$

Acidic buffer with non-mercury stabilizer, spiked with defined quantity of adrenaline, noradrenaline Content: and dopamine

 $riangle \mathbb{R}^{+}$ st for the determination of dopamine in plasma the additional **Standard A/B** is mandatory!

Additional materials required but not provided in the kit 4.3

- Water (deionized, distilled, or ultra-pure)
- Absorbent material (paper towel)

Additional equipment required but not provided in the kit 4.4

- Calibrated precision pipettes to dispense volumes between 10 700 ul; 1 ml
- Microtiter plate washing device (manual, semi-automated or automated)
- ELISA reader capable of reading absorbance at 450 nm and if possible 620 650 nm
- Microtiter plate shaker (shaking amplitude 3 mm; approx. 600 rpm)
- Vortex mixer

Version: 20.0-r Effective: 2025-05-20 6 / 13

Sample collection, handling and storage

Plasma

Whole blood should be collected into centrifuge tubes containing EDTA as anti-coagulant and centrifuged according to manufacturer's instructions immediately after collection.

In case of hemolytic, icteric or lipemic samples see 2.2.1.

Storage: up to 6 hours at 2 - 8 °C, for longer period (up to 6 months) at -20 °C.

Repeated freezing and thawing should be avoided.

Urine

Spontaneous urine or 24-hour urine, collected in a bottle containing 10 - 15 ml of 6 M HCl, can be used.

If 24-hour urine is used please record the total volume of the collected urine.

Storage: up to 48 hours at 2 - 8 °C, up to 24 hours at room temperature, for longer periods (up to 6 months) at -20 °C. Repeated freezing and thawing should be avoided. Avoid exposure to direct sunlight.

Test procedure

Allow all reagents and samples to reach room temperature and mix thoroughly by gentle inversion before use. Number the Extraction Plate and microwell plates (Microtiter Strips which are removed from the frame for usage should be marked accordingly to avoid any mix-up). Duplicate determinations are recommended.

The binding of the antisera and of the enzyme conjugate and the activity of the enzyme are temperature dependent. The higher the temperature, the higher the absorption values will be. Varying incubation times will have similar influences on the absorbance. The optimal temperature during the enzyme immunoassay is between 20 - 25 °C.

 $\stackrel{\text{$(1)}}{\text{(2)}}$ The use of a microtiter plate shaker with the following specifications is mandatory: shaking amplitude 3 mm; approx. 600 rpm. Shaking with differing settings might influence the results.

riangleIn case of overflow, read the absorbance of the solution in the wells within 10 minutes, using a microplate reader set to 405 nm.

Preparation of reagents and further notes

Dilute the 20 ml Wash Buffer Concentrate WASH-CONC 50X with water to a final volume of 1000 ml.

Storage: 2 months at 2 - 8 °C

Enzyme Solution

Enzyme Solution

Reconstitute the content of the vial **ENZYME** with 1 ml water (deionized, distilled, or ultra-pure) and mix thoroughly. Add 0.3 ml of **COENZYME** followed by 0.7 ml of **ADJUST-BUFE** The total volume of the Enzyme Solution is 2.0 ml.

 $\stackrel{/!}{\square}$ The Enzyme Solution has to be prepared freshly prior to the assay (not longer than 10 – 15 minutes in advance). Discard after use!

Adrenaline Microtiter Strips, Noradrenaline Microtiter Strips and Dopamine Microtiter Strips

In rare cases residues of the blocking and stabilizing reagent can be seen in the wells as small, white dots or lines. These residues do not influence the quality of the product.

Acylation Reagent
The ACYL-REAG (BA E-6612) has a freezing point of 18.5 °C. To ensure that it is liquid when being used, it must be Please use only the valid ensured that it has reached room temperature and forms a homogeneous, crystal-free solution before being used.

Version: 20.0-r Effective: 2025-05-20 7 / 13

6.2 Sample preparation, extraction and acylation

 $riangle \mathbb{L}$ st for the determination of dopamine in plasma the additional **Standard A/B** is mandatory!

- 1. Pipette 10 μl of standards, controls, urine samples and 300 μl of plasma samples into the respective wells of the EXTRACT-PLATE 48.
- 2. Add 250 µl of water (deionized, distilled, or ultra-pure) to the wells with standards, controls and urine samples.
- **3.** Pipette **50** μ I of **ASSAY-BUFF** into all wells.
- **4.** Pipette **50 μI** of **EXTRACT-BUFF** into all wells.
- 5. Cover plate with **FOILS** and incubate **30 min** at **RT** (20 25 °C) on a **shaker** (approx. 600 rpm).
- 6. Remove the foil. Empty plate and blot dry by tapping the inverted plate on absorbent material.
- 7. Pipette 1 ml of Wash Buffer into all wells. Incubate the plate for 5 min at RT (20 25 °C) on a shaker (approx. 600 rpm). Empty plate and blot dry by tapping the inverted plate on absorbent material.
- 8. Pipette another 1 ml of Wash Buffer into all wells. Incubate the plate for 5 min at RT (20 25 °C) on a shaker (approx. 600 rpm). Empty plate and blot dry by tapping the inverted plate on absorbent material.
- **9.** Pipette **150** μ **I** of **ACYL-BUFF** into all wells.
- **10.** Pipette **25** μ I of **ACYL-REAG** into all wells.
- **11.** Incubate **15 min** at **RT** (20 25 °C) on a shaker (approx. 600 rpm).
- 12. Empty plate and blot dry by tapping the inverted plate on absorbent material.
- 13. Pipette 1 ml of Wash Buffer into all wells. Incubate the plate for 10 min at RT (20 25 °C) on a shaker (approx. 600 rpm). Empty plate and blot dry by tapping the inverted plate on absorbent material.
- **14.** Pipette **175** μ I of HCL into all wells.
- **15.** Cover plate with **FOILS**. Incubate **10 min** at **RT** (20 25 °C) on a **shaker** (approx. 600 rpm). Remove the foil and discard.
- ↑ Do not decant the supernatant thereafter!

The following volumes of the supernatant are needed for the subsequent ELISA:

Adrenaline	100 µl	Noradrenaline	20 μΙ
	1111		
Dopamine (standards + urine)	25 μ⊅	Dopamine (plasma)	50 µl

6.3 Adrenaline ELISA

- 2. Pipette 100 μ I of the extracted standards, controls and samples into the appropriate wells.
- 3. Incubate for 30 min at RT (20 25 °C) on a shaker (approx. 600 rpm).
- 4. Pipette 50 µl of the ADR-AS into all wells and cover plate with FOILS.
- **5.** Incubate for **2 h** at **RT** (20 25 °C) on a **shaker** (approx. 600 rpm).
- 6. Remove the foil. Discard or aspirate the content of the wells. Wash the plate 3 x by adding 300 μI of Wash Buffer, discarding the content and blotting dry each time by tapping the inverted plate on absorbent material.
- 7. Pipette 100 pof the CONJUGATE into all wells.
- 8. Incubate for 30 min at RT (20 25 °C) on a shaker (approx. 600 rpm).
- 9. Discard or aspirate the content of the wells. Wash the plate 3 x by adding 300 μl of Wash Buffer, discarding the content and blotting dry each time by tapping the inverted plate on absorbent material.
- 10. Ripette 100 μl of the SUBSTRATE into all wells and incubate for 25 ± 5 min at RT (20 25 °C) on a shaker (approx. 600 rpm). Avoid exposure to direct sunlight!
- 11. Add 100 µl of the STOP-SOLN to all wells and shake the microtiter plate shortly.
- **12. Read** the absorbance of the solution in the wells within 10 minutes, using a microplate reader set to **450 nm** (if available a reference wavelength between 620 nm and 650 nm is recommended).

Version: 20.0-r Effective: 2025-05-20 **8 / 13**

6.4 Noradrenaline ELISA

- 1. Pipette 25 μ I of the Enzyme Solution (refer to 6.1) into all wells of the Noradrenaline Microtiter Strips \square NAD NMN.
- 2. Pipette 20 μ I of the extracted **standards**, **controls** and **samples** into the appropriate wells.
- 3. Incubate for 30 min at RT (20 25 °C) on a shaker (approx. 600 rpm).
- **4.** Pipette **50** μ**I** of the **NAD-AS** into all wells and cover plate with **FOILS**.
- 5. Incubate for 2 h at RT (20 25 °C) on a shaker (approx. 600 rpm).
- **6.** Remove the foil. Discard or aspirate the content of the wells. Wash the plate **3 x** by adding **300 μI** of **Wash Buffer**, **discarding** the content and **blotting dry each time** by tapping the inverted plate on absorbent material.
- 7. Pipette 100 μ I of the **CONJUGATE** into all wells.
- 8. Incubate for 30 min at RT (20 25 °C) on a shaker (approx. 600 rpm).
- 9. Discard or aspirate the content of the wells. Wash the plate 3 x by adding 300 μl of Wash Buffer, discarding the content and blotting dry each time by tapping the inverted plate on absorbent material.
- 10. Pipette 100 μl of the SUBSTRATE into all wells and incubate for 25 ± 5 min at RT (20 25°C) on a shaker (approx. 600 rpm).

 Δ Avoid exposure to direct sunlight!
- 11. Add 100 µl of the STOP-SOLN to all wells and shake the microtiter plate shortly.
- **12. Read** the absorbance of the solution in the wells within 10 minutes, using a microplate reader set to **450 nm** (if available a reference wavelength between 620 nm and 650 nm is recommended).

6.5 Dopamine ELISA

- 2. Pipette 25 μl of the extracted standards, controls, urine samples and 50 μl of the extracted plasma samples into the appropriate wells.
- 3. Add 25 μ I of HCL to the standards, controls and urine samples.
- 4. Incubate for 30 min at RT (20 25 °C) on a shaker (approx. 600 rpm).
- 5. Pipette 50 µl of the NAD-AS into all wells and cover plate with FOILS.
- **6.** Incubate for **2 h** at **RT** (20 25 °C) on a **shaker** (approx. 600 rpm).
- 7. Remove the foil. Discard or aspirate the content of the wells. Wash the plate 3 x by adding 300 µl of Wash Buffer, discarding the content and blotting dry each time by tapping the inverted plate on absorbent material.
- 8. Pipette 100 μl of the CONJUGATE into all wells.
- 9. Incubate for **30 min** at **RT** (20 > 25 °C) on a **shaker** (approx. 600 rpm).
- 10. Discard or aspirate the content of the wells. Wash the plate 3 x by adding 300 μl of Wash Buffer, discarding the content and blotting dry each time by tapping the inverted plate on absorbent material.
- 11. Pipette 100 μ l of the **SUBSTRATE** into all wells and incubate for 25 \pm 5 min at RT (20 25 °C) on a **shaker** (approx 600 rpm). \triangle **Avoid exposure to direct sunlight!**
- 12. Add 100 µl of the STOP-SOLN to all wells and shake the microtiter plate shortly.
- **13. Read** the absorbance of the solution in the wells within 10 minutes, using a microplate reader set to **450 nm** (it available a reference wavelength between 620 nm and 650 nm is recommended).

7. Calculation of results

PIG		Adrenaline	Noradrenaline	Dopamine
Measuring range	Urine	0.7 - 200 ng/ml	2.5 - 1,000 ng/ml	4.8 - 2,000 ng/ml
	Plasma	18 - 6,667 pg/ml	93 – 33,333 pg/ml	75 – 33,333 pg/ml

The standard curve, which can be used to determine the concentration of the unknown samples, is obtained by plotting the absorbance readings (calculate the mean absorbance) of the standards (linear, y-axis) against the corresponding standard concentrations (logarithmic, x-axis) using a concentration of 0.001 ng/ml for Standard A (this alignment is mandatory because of the logarithmic presentation of the data). Use non-linear regression for curve fitting (e.g. 4-parameter, marquardt).

This assay is a competitive assay. This means: the OD-values are decreasing with increasing concentrations of the analyte. OD-values found below the standard curve correspond to high concentrations of the analyte in the sample and have to be reported as being positive.

Urine samples and controls

The concentrations of the **urine samples** and the **Controls** can be read directly from the standard curve. Calculate the 24 h excretion for each urine sample: $\mu g/24h = \mu g/l \times l/24h$

Plasma samples


The read Adrenaline and Noradrenaline concentrations of the plasma samples have to be divided by 30. The read **Dopamine** concentrations of the **plasma samples** have to be **divided by 60.**

Conversion:

Adrenaline $[ng/ml] \times 5.46 = Adrenaline [nmol/l]$ Noradrenaline $[ng/ml] \times 5.91 = Noradrenaline [nmol/l]$ Dopamine $[ng/ml] \times 6.53 = Dopamine [nmol/l]$

7.1 Typical standard curve

Examples: Do not use for calculation!



8. Control samples

The confidence limits of the kit controls are indicated on the QC-Report.

9. Assay characteristics

9.1 Performance data

Analytical Sensitivity						
	3,5	Adrenaline	Noradrenaline	Dopamine		
Limit of Plank (LOP)	Urine [ng/ml]	0.8	1.5	2.2		
Limit of Blank (LOB)	Plasma [pg/ml]	9.3	32	43		
Limit of Detection (LOD)	Urine [ng/ml]	0.9	1.7	2.5		
Limit of Detection (LOD)	Plasma [pg/ml]	10	36	49		
Limit of Overhiliantian (1991)	Urine [ng/ml]	0.7	2.5	4.8		
Limit of Quantification (LOQ)	Plasma [pg/ml]	18	93	75		

Version: 20.0-r Effective: 2025-05-20 10 / 13

Analytical Specificity (Cross Reactivity)						
Substance	Cross Reactivity [%]					
Substance	Adrenaline	Noradrenaline	Dopamine			
Derivatized Adrenaline	100	0.08	0.02			
Derivatized Noradrenaline	0.13	100	6.4			
Derivatized Dopamine	< 0.01	0.03	100			
Metanephrine	0.18	< 0.01	< 0.01			
Normetanephrine	< 0.01	0.16	0.01			
3-Methoxytyramine	< 0.01	< 0.01	0.49			
3-Methoxy-4-hydroxyphenylglycol	< 0.01	< 0.01	< 0.01			
Tyramine	< 0.01	< 0.01	0.18			
Phenylalanine, Caffeinic acid, L-Dopa, Homovanillic acid, Tyrosine, 3-Methoxy-4-hydroxymandelic acid	< 0.01	< 0.01	(0.01			

						74.	
Precision						::480	
Intra-Assay Urin	e (n = 60)			Intra-Assay Plasma (n = 60)			
	Sample	Range [ng/ml]	CV [%]		Sample	Range [pg/ml]	CV [%]
Adrenaline	1	6.2 ± 1.1	17.4	Adrenaline	.0	64.7 ± 15.9	24.7
	2	21.4 ± 2.7	12.4		2	258 ± 32.5	12.7
	3	59.4 ± 7.8	13.1	(0)	3	948 ± 105	11.0
Noradrenaline	1	26.1 ± 3.6	13.8	Noradrenaline	1	510 ± 65	12.8
	2	97 ± 12.8	13.4	×iOl'	2	1,358 ± 194	14.3
	3	267 ± 35	13.1	W.	3	3,363 ± 374	11.1
Dopamine	1	82 ± 16.1	19.7	Dopamine	1	75 ± 22	29.8
	2	253 ± 41.1	16.3		2	353 ± 86	24.4
	3	714 ± 67	9.4		3	1,187 ± 293	24.9
Inter-Assay Urin	e (n = 33)		O,	Inter-Assay Plasma (n = 18)			
	Sample	Range [ng/ml]	CV [%]		Sample	Range [pg/ml]	CV [%]
Adrenaline	1	5.2 ± 0.9	17.9	Adrenaline	1	76.4 ± 11.1	14.5
	2	17.8 ± 2.1	11.7		2	247 ± 27.5	11.1
	3	54.2 ± 6.6	12.1		3	771 ± 101	13.1
Noradrenaline	1	19.5 ± 3.9	20.0	Noradrenaline	1	445 ± 40.9	9.2
	2 💉	80.6 ± 10.6	13.2		2	1,232 ± 134	10.9
	34	226 ± 39.5	17.4		3	3,283 ± 302	9.2
Dopamine	01	79.3 ± 18.8	23.7	Dopamine	1	238 ± 67.0	28.2
	<u>2</u>	222 ± 27.0	12.1		2	1,072 ± 201	18.8
	3	630 ± 69.0	11.0	1	3	3,449 ± 491	14.2

Lot-to-Lot	Lot-to-Lot					
		Sample	Mean ± SD [ng/ml]	CV [%]		
Adrenaline (n = 5)	Urine	1	6.6 ± 0.9	13.7		
		2	23.5 ± 1.5	6.2		
	Diagrap	Sample	Mean ± SD [pg/ml]	CV [%]		
	Plasma	1	202 ± 26.7	11.8		
	Urine	Sample	Mean ± SD [ng/ml]	CV [%]		
		1	124 ± 13.2	10.7		
Noradrenaline (n = 6)		2	29.3 ± 3.7	12.6		
(11 – 0)	Discourse	Sample	Mean ± SD [pg/ml]	CV [%]		
	Plasma	1	1,071 ± 97.3	5.3		
Dopamine (n = 6)		Sample	Mean ± SD [ng/ml]	CV [%]		
	Urine	1	189 ± 14.7	7.8		
		2	678 ± 39.3	5.8		

Recovery was determined according to the CLSI standard EP 34 1st ed.

Recovery			,0%	
	Urine	Range [ng/ml]	Mean [%]	Range [%]
Adronalina	Offile	0.27 - 61	95	89 – 98
Adrenaline	Plasma	Range [pg/ml]	Mean [%]	Range [%]
	PlaSilia	9.1 - 4,268	105	88 - 117
	Urine	Range [ng/ml]	Mean [%]	Range [%]
Noradrenaline	onne	1.8 - 249	96	70 - 118
Noraurenanne	Disamo	Range [pg/ml]	Mean [%]	Range [%]
	Plasma	51 - 14,251	87	75 – 107
	Urino	Range [ng/m/]	Mean [%]	Range [%]
Dopamine	Urine	9.2 - 762	112	106 - 117
	Disamo	Range [pg/ml]	Mean [%]	Range [%]
	Plasma	574 - 16,054	89	84 - 92

Linearity						
		Serial dilution up to	Mean [%]	Range [%]		
Adrenaline	Urine	1:512	108	92 - 123		
Aurenaline	Plasma	1:512	105	94 - 115		
Novedvonsline	Urine	1:512	112	100 - 127		
Noradrenaline R	Plasma	1:512	112	102 - 125		
Dopamine	Urine	1:512	104	83 - 126		
	Plasma	1:512	106	85 - 132		

9.2 Metrological Traceability

The values assigned to the standards and controls of the 3-CAT ELISA Fast Track are traceable to SI Units by weighing with quality-controlled analyte.

Standards and Controls				
	Uncertainty [%]			
Adrenaline	3.5			
Noradrenaline	4.1			
Dopamine	2.5			

Version: 20.0-r *Effective: 2025-05-20* **12 / 13**

3-CAT ELISA Fast Track				
Adrenaline	Urine	Concentration [ng/ml]	Expanded Uncertainty [%] k = 2*	
		5.2	36.5	
		17.8	24.4	
		54.2	25.2	
	Plasma	Concentration [pg/ml]	Expanded Uncertainty [%] k = 2*	
		76.4	29.8	
Noradrenaline	Urine	Concentration [ng/ml]	Expanded Uncertainty [%] k = 2*	
		19.5	40.8	
		80.6	27.6	
		226	35.7	
	Plasma	Concentration [pg/ml]	Expanded Uncertainty [%) k = 2*	
		445	20.1	
Dopamine	Urine	Concentration [ng/ml]	Expanded Uncertainty [%] k = 2*	
		79.3	7.7	
		222	24.7	
		630	22.6	
	Plasma	Concentration [pg/ml]	Expanded Uncertainty [%] k = 2*	
		238	56.6	

^{*} This defines an interval about the measured result that will include the true value with a probability of 95%.

10. References/Literature

- 1. Kim, H., et al., Vitamin C prevents stress-induced damage on the heart caused by the death of cardiomyocytes, through down-regulation of the excessive production of catecholamine, TNF-a, and ROS production in Gulo(-/-)Vit C-Insufficient mice. Free Radio Biol Med, 2013. **65**: p. 573-583.
- 2. Bada, A.A., et al., *Peripheral vasodilatation determines cardiac output in exercising humans: insight from atrial pacing.* J Physiol, 2012. **590**(8): p. 2051-60.
- 3. Parks, C.G., et al., *Employment and work schedule are related to telomere length in women.* Occup Environ Med, 2011. **68**(8): p. 582-9.
- 4. Eisenhofer, G., C. Pamporaki, and J.W.M. Lenders, *Biochemical Assessment of Pheochromocytoma and Paraganglioma*. Endocr Rev, 2023. **44**(5): p. 862-909.

For updated literature or any other information please contact your local supplier.

11. Changes

Version	Release Date	Chapter	Change
19.0-r	2023-11-28	4.1	- Hazard labelling updated according to SDS
20.0-r	2025-05-20 ONY THE	2.1 2.2.2 4.1 9.1 9.2 10	 Updated Drugs + foods that affect concentrations of catecholamines added BA E-0040: Hazard labelling updated according to SDS Lot-to-lot added; recovery urine updated Metrological Traceability added Updated

Symbols:

